Skip to content

Author

R. Frikke-Schmidt

We have 5 of 424 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

The Half-Life of Long Forms of Cardiac Troponin T.

BACKGROUND Long forms of cardiac troponin T (cTnT) are promising markers that may differentiate myocardial infarction from other causes of acute and chronic myocardial injury. However, to understand the clinical utility of long cTnT, knowledge of the half-life (T½) is key. By using auto-transfusion in humans we determi...

R. Hasselbalch, S. Salonen, J. Kristensen et al. · 0 citations
Open access Aug 2026

Glycaemic variation and atrial fibrillation burden and progression in individuals without diabetes undergoing continuous rhythm monitoring.

BACKGROUND Glycaemic dysregulation is associated with clinically diagnosed atrial fibrillation (AF), but prior studies have largely relied on limited monitoring of heart rhythm and glucose levels. We investigated whether periods with higher glucose exposure were associated with AF burden and progression in individuals...

A. K. Hessellund, K. Haugan, L. Y. Xing et al. · 1 citation
Open access Aug 2026

Genetic architecture of cytokine autoantibodies and associated risk of common diseases

Genetic predisposition to IL-1α autoantibodies is associated with reduced risk of rheumatoid arthritis and certain cancers, whereas genetic predisposition to IL-6 autoantibodies is associated with increased risk of diabetes, mirroring prior clinical observations.

J. V. von Stemann, Joseph Dowsett, R. Teglgaard et al. · 0 citations
Aug 2026

Prevalence of Silent Atherosclerosis across Adult Life.

This study of silent atherosclerosis showed that the disease was detectable in early adulthood, with age- and sex-associated increases in prevalence across arterial territories and marked increases in plaque volume.

H. Bundgaard, I. García-Lunar, K. F. Kofoed et al. · 0 citations
Open access Aug 2026

Exome analysis of 22,319 individuals links extremely rare copy-number variants and 22q11.21 dosage to Alzheimer risk.

It is concluded that rare coding CNVs in a proportion of AD-associated genes and 22q11.21 duplication as a strong AD-risk-decreasing factor increase AD risk and Conversely, 22q11.21 duplication as a strong AD-risk-decreasing factor is identified.

O. Quenez, Catherine Schramm, K. Cassinari et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.